LLY
Eli Lilly and Company
1,181.90$
+2.7%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.1% | -3.3% | 13.3% | 13.0% | 32.4% | 18.3% | 13.1% | 19.8% | 50.2% | 16.7% | 26.9% | 46.5% | 35.3% | |
| 4.3% | 4.1% | 4.6% | 3.7% | 4.1% | 3.6% | 3.6% | 3.1% | 2.7% | 3.0% | 2.6% | 2.3% | 2.6% | |
| 2.3% | 1.3% | 1.8% | 1.9% | 1.2% | 1.0% | 1.2% | 1.2% | 0.9% | 0.7% | 0.8% | 0.9% | 0.8% | |
| 11.0% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 8.4% | -33.9% | -20.0% | -12.4% | -0.1% | -16.4% | -26.4% | -14.5% | 6.9% | -19.0% | -8.4% | -2.9% | -6.0% | |
| 42.1% | 17.7% | 11.2% | 12.4% | 36.5% | 12.9% | 25.7% | 11.6% | 1.3% | 13.2% | 11.7% | 12.8% | 10.1% | |
| -32.4% | -31.3% | -13.4% | -19.5% | -35.0% | -14.2% | -26.3% | -11.8% | -16.9% | -14.5% | -19.8% | -67.0% | -31.5% | |
| 10.7% | 10.9% | 13.3% | 10.4% | 10.2% | 8.6% | 10.6% | 8.7% | 7.6% | 7.0% | 7.8% | 6.7% | 7.3% | |
| -7.9% | 8.0% | 0.0% | 0.0% | -3.9% | -15.2% | -9.4% | -4.4% | -4.0% | -7.8% | -11.9% | -7.0% | -7.7% | |
| 16.8% | – | – | – | 16.4% | 22.5% | 36.2% | 5.3% | 14.9% | 0.0% | 5.2% | 50.4% | 19.1% | |
| 6.0% | 37.9% | -3.6% | 13.8% | 1.8% | -1.7% | 10.8% | -8.0% | 3.0% | -14.9% | -17.5% | 36.7% | 3.3% | |
| -3.3% | 4.7% | -4.1% | 6.8% | 1.3% | -0.7% | -1.4% | 1.8% | 36.5% | -13.1% | -10.0% | 16.0% | 7.0% | |
| -19.1% | -21.0% | 2.0% | 0.6% | -4.0% | 5.4% | -12.6% | 8.2% | 48.9% | 3.5% | 15.2% | 33.8% | 25.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.